Black Lung Disease Market Report 2026

The black lung disease market size has grown rapidly in recent years. It will grow from $10.92 billion in 2025 to $12.51 billion in 2026 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to increasing coal mining activities, prolonged exposure to coal dust among miners, limited early diagnostic access in mining regions, rising incidence of respiratory occupational diseases, dependence on traditional diagnostic methods.

The black lung disease market size is expected to see rapid growth in the next few years. It will grow to $22.5 billion in 2030 at a compound annual growth rate (CAGR) of 15.8%. The growth in the forecast period can be attributed to increasing adoption of advanced diagnostic technologies, rising investments in occupational health programs, growing research in stem cell and regenerative therapies, expansion of healthcare access in mining regions, increasing regulatory enforcement on worker health safety. Major trends in the forecast period include improved diagnostic imaging for early detection, growing focus on preventive occupational health screening, rising adoption of advanced pulmonary function testing, expansion of research into regenerative therapies, enhanced monitoring of coal dust exposure.

The rise in mining activities is expected to drive the growth of the black lung disease market in the coming years. Mining activities involve the extraction of valuable minerals, ores, and other geological materials from the earth's crust. Black lung disease results from mining operations and the inhalation of coal mine dust, which contains harmful carbon-based particles and primarily affects coal miners. For example, in July 2024, the International Energy Agency (IEA), a France-based intergovernmental organization, reported that global coal production in 2023 increased by 3.1% to 8,970 Mt, reaching an all-time high, driven by major coal producers such as China, India, and Indonesia. Thus, the growth of mining activities is contributing to the expansion of the black lung disease market.

The rising prevalence of tuberculosis is expected to drive the growth of the black lung disease market in the coming years. Tuberculosis is a bacterial infection primarily caused by Mycobacterium tuberculosis. It spreads through the air when an infected individual coughs or sneezes and can cause symptoms such as coughing, fever, weight loss, and fatigue. The increasing prevalence of tuberculosis (TB) contributes to black lung disease because individuals with TB are at a higher risk of developing black lung disease and are more likely to be exposed to coal dust. For example, in November 2024, the Centers for Disease Control and Prevention, a US-based national public health organization, reported that in 2023, TB cases and the incidence rate (number of TB cases per 100,000 persons) in the United States increased for the third consecutive year. Consequently, the growing prevalence of tuberculosis is fueling the expansion of the black lung disease market.

Government funding initiatives are anticipated to drive the growth of the black lung disease market. Government funding refers to financial support provided by a government, typically at the federal, state, or local level, to aid various activities, programs, projects, initiatives, or organizations that serve public interests or fulfill government objectives. Authorities are implementing specific regulations and programs to protect coal miners from black lung disease. For example, in June 2024, according to the United States Congress, the US-based legislative branch of the federal government, the FY2025 budget request proposed an NIH and ARPA-H program level of $50.174 billion, reflecting an increase of $1.363 billion (+2.8%) over the FY2024-enacted level. As a result, government funding initiatives are supporting the growth of the black lung disease market.

Major companies operating in the black lung disease market are Pfizer Inc., Johnson and Johnson, Siemens AG, General Electric, F. Hoffmann-La Roche AG, Merck and Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Medtronic plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Toshiba Corporation, Koninklijke Philips N.V., Mayo Clinic, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Hikma Pharmaceuticals plc, Lupin Limited.

North America was the largest region in the black lung disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the black lung disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the black lung disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the black lung disease market by increasing costs of imported diagnostic imaging equipment, pulmonary testing devices, laboratory reagents, and advanced medical instruments used in diagnosis and treatment. Healthcare providers and diagnostic centers in North America and Europe are most affected due to reliance on imported medical technologies, while developing mining regions face higher procurement costs for modern diagnostic tools. These tariffs are increasing healthcare expenditure and slowing technology upgrades in occupational health facilities. However, they are also encouraging domestic manufacturing of medical devices, localized production of diagnostic equipment, and investment in regional healthcare infrastructure focused on occupational disease management.

The black lung disease market research report is one of a series of new reports that provides black lung disease market statistics, including black lung disease industry global market size, regional shares, competitors with a black lung disease market share, detailed black lung disease market segments, market trends and opportunities, and any further data you may need to thrive in the black lung disease industry. This black lung disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Black lung disease is a chronic and potentially life-threatening lung condition that affects coal miners and other individuals working in coal mines or exposed to coal dust. It is marked by the buildup of coal dust particles in the lungs, which can result in inflammation, scarring, and damage to lung tissue.

The main forms of black lung disease include simple coal workers’ pneumoconiosis, complicated coal workers’ pneumoconiosis, and others. Simple coal workers’ pneumoconiosis (CWP), also referred to as simple black lung disease, is a lung disorder caused by prolonged inhalation of coal dust. Treatments include oxygen therapy, bronchodilators, lung transplants, stem cell therapy, and other approaches, and diagnosis may involve biopsy, imaging, complete blood count, pulmonary or lung function tests, physical examination, and more. These services are utilized by various end-users, including hospitals and clinics, research organizations and academic institutions, diagnostic centers and laboratories, and others.

The black lung disease market includes revenues earned by entities by providing pulmonary rehabilitation (PR), medical services and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.